Reversible Cardiomyopathy in Paediatric Addison’s Disease - A Cautionary Tale

L.S. Conwell¹, L.M. Gray², R.G. Delbridge³, M.J. Thomsett¹ and J.A. Batch¹

¹Department of Endocrinology and Diabetes and ³Paediatric Intensive Care Unit, Royal Children’s Hospital, Brisbane and ²Rockhampton, Queensland, Australia

ABSTRACT

A 13 year-old girl with clinical features of Addison’s disease developed acute cardiac failure after initiation of treatment and after initial clinical improvement. Large doses of i.v. hydrocortisone and oral fludrocortisone, in addition to inotropic and ventilatory support, were required to achieve cardiovascular stability. The cardiomyopathy improved over one week and her condition then remained stable on oral glucocorticoid and mineralocorticoid replacement therapy. Reversible cardiomyopathy is a rare and potentially life-threatening complication of Addison’s disease. The second reported paediatric patient is presented, the only one reported to require ventilatory support.

KEY WORDS

adrenal failure, Addison’s disease, myocardium, cardiomyopathy

INTRODUCTION

Acquired autoimmune adrenal failure may occur alone or as a manifestation of either autoimmune polyendocrinopathy type 1 or type 2 syndromes. It is the commonest cause of primary adrenal failure in developed countries, accounting for 75-90% of cases¹.

This report describes reversible cardiomyopathy in a child with Addison’s disease. There is only one previous report of such a case. An 11 year-old boy developed cardiac failure 24 hours after treatment with intravenous fluids and hydrocortisone². In comparison, the patient in this report required increased inotropic support and mechanical ventilatory support.

PATIENT REPORT

A 13 year-old girl presented with 3 weeks of weight loss, lethargy, weakness, abdominal cramping, vomiting and salt-craving. Increasing skin pigmentation had been apparent for several months. Her past medical and family history was unremarkable.

Physical examination revealed a cachectic, weak and hyperpigmented girl. Her temperature was 35.2°C, respiratory rate 20/min, heart rate 105/min, blood pressure 65/30 mmHg and peripheral perfusion poor.

Initial investigations demonstrated sodium 121 mmol/l (normal 137-147), potassium 7.0 mmol/l (3.5-5.0), creatinine 0.14 mmol/l (0.04-0.10), chloride 93 mmol/l (96-109), bicarbonate 14 mmol/l (25-33), venous pH 7.3 (7.3-7.4), glucose 4.2 mmol/l (3.0-7.7), corrected calcium 3.45 mmol/l (2.25-2.65), magnesium 0.4 mmol/l (0.7-1.1) and lactate 1.1 mmol/l (0.6-2.0).

A provisional diagnosis of acute adrenal insufficiency was made. Early morning cortisol measured on a sample collected 7 days before presentation was 27 nmol/l (1.0 μg/dl) (normal 200-700 nmol/l [7-25 μg/dl]). ACTH could not be measured prior to treatment. Adrenal auto-antibodies were subsequently positive (1:160) confirming the diagnosis of autoimmune Addison’s disease.
Intravenous fluids, intravenous hydrocortisone (100 mg q 6 h) and oral fludrocortisone (100 μg bid) were commenced. Despite marked initial improvement, respiratory distress and hypotension developed 36 hours after admission. Basal respiratory crackles were present without peripheral oedema. Despite initial hypovolaemia, the patient was only in 1.2 l positive fluid balance. The chest X-ray was consistent with extensive pulmonary oedema (Fig. 1).

After initiation of intravenous broad-spectrum antibiotics, intravenous magnesium bolus, diuretic therapy and inotropic support (dopamine 5 μg/kg/min), the patient was transferred to a tertiary paediatric intensive care unit.

Increasing inotropic support was required (dopamine 7.5 μg/kg/min and dobutamine 10 μg/kg/min). Echocardiography revealed a non-dilated left ventricle, mild mitral regurgitation and global reduction in left ventricular fractional shortening to 24% (normal 26-40%). Cardiac troponin I was mildly elevated at 2.2 ng/l (<0.4 ng/l). Ventilation was supported with mask continuous positive airway pressure (CPAP) for 2 days. Intubation and ventilation were then required due to intolerance of mask CPAP and the ongoing requirement for respiratory support. The patient did not develop acidosis during this period. Intravenous hydrocortisone and oral fludrocortisone doses were increased to achieve cardiovascular stability (maximal doses of 100 mg q 3 h and 300 μg tid, respectively). Extubation was achieved on day 8, with cessation of inotropic support on day 9.

Nasopharyngeal aspirates were negative for respiratory viruses. Blood cultures were negative. Initial thyroid function tests at presentation showed an elevated TSH level of 8 mU/l (normal 0.4-5 mU/l) with normal fT4. The TSH had normalised on repeat testing and thyroid autoantibodies were negative.

Left ventricular fractional shortening had increased to 32% by day 12. Trivial mitral regurgitation persisted. ECG on day 21 showed T-wave inversion in leads 1, AVL and V6. Hypomagnesaemia persisted, requiring oral supplementation for 3 weeks. The patient’s condition then remained stable on oral glucocorticoid and mineralocorticoid replacement therapy, and was weaned to expected physiological doses by day 17. Echocardiography 5 months later demonstrated stable myocardial contractility with low-normal left ventricular fractional shortening and improved mitral valve function.

**DISCUSSION**

Potential factors contributing to myocardial dysfunction in this patient with Addison’s disease include chronic glucocorticoid deficiency, mineralocorticoid deficiency, ischaemia and hypomagnesaemia.

Other examples of reversible cardiomyopathy in the context of glucocorticoid deficiency have been described, including a neonate with congenital adrenal hyperplasia and a 36 year-old man with Addison’s disease. A 6 year-old boy, subsequently diagnosed with adrenoleukodystrophy, died due to primary myocardial pump failure. In contrast to these patients, the reported patient’s cardiac func-
tion deteriorated after the commencement of treatment and after initial clinical improvement.

Hypovolaemia and/or electrolyte imbalance are not essential in the pathogenesis of circulatory collapse observed in adrenal insufficiency. Corticosteroids play a key role in the regulation of circulatory function. Glucocorticoids are important for intrinsic myocardial contractility and regulation of the sympathetic nervous system. Adrenalectomised animals demonstrate diminished myocardial function with impaired adenosine triphosphatase activity, calcium transport, and compartmentalisation of phosphorylase in heart muscle. Glucocorticoid deficiency downregulates adrenergic receptors, and decreases epinephrine synthesis, tissue sensitivity to catecholamines and epinephrine activation of glycogenolysis in the myocardium. Sympathectomy and α- and β-blockade protect stressed adrenalectomised animals from circulatory failure. It has been proposed that catecholamines may have a detrimental effect on the heart in the absence of a corresponding increase in glucocorticoid, due to an increase in intracellular lactate and impaired contractility. Aldosterone exerts a positive inotropic action; therefore mineralocorticoid deficiency may also contribute to myocardial dysfunction.

Cardiac troponin I is a very sensitive and specific marker for myocardial cell necrosis, with levels remaining elevated for 7-10 days after an episode of myocardial necrosis. Although there were no acute ischaemic ECG features, inverted T waves were apparent at Day 21. In this case, ischaemic injury may have been a secondary effect rather than the primary causative insult. Glucocorticoid deficiency may lower the threshold for ischaemic injury.

In addition to impaired cardiac output, hypotension in Addison’s disease is due to hypovolaemia secondary to renal salt loss and vomiting; and increased production of the vasodilator bradykinin and decreased vascular reactivity, both due to glucocorticoid deficiency. Lower levels of α1-adrenergic receptors and angiotensin-I receptors have been described. Although plasma angiotensin II levels are high and contribute to the maintenance of peripheral resistance, the effectiveness of angiotensin II is blunted.

Although congestive cardiac failure associated with fludrocortisone treatment has been described in patients with Addison’s disease, the patient reported here had only received two 100 μg doses of oral fludrocortisone.

Acute viral myocarditis is a common cause of reversible myocardial dysfunction in children and adolescents. Viruses such as cytomegalovirus have been implicated in the pathogenesis of adrenal insufficiency in immunocompromised states, e.g. AIDS. However the patient was immunocompetent and did not have a history of fever or respiratory symptoms in the 10-14 days prior to presentation. Symptoms and signs of primary adrenal insufficiency had been present for months preceding the myocardial compromise, suggesting that a viral agent was not simultaneously contributing to acute myocarditis and adrenalitis.

Hypomagnesaemia may contribute to cardiac dysfunction. Low magnesium levels are common in seriously ill patients, including those with acute myocardial infarction or heart failure. Magnesium modulates mechanical and electrical functions of cardiac and vascular cells, and animals fed on a low magnesium diet have developed cardiomyopathy. Hypercalcaemia, as evident in this reported patient, has been previously associated with Addison’s disease, with resolution after correction of cortisol deficiency. Although glucocorticoid receptors are present in bone cells, the mechanism is poorly understood. A PTH effect is discounted due to hypercalcaemia in an Addisonian patient with co-existent idiopathic hypoparathyroidism. Documented persistence despite intravenous rehydration suggests haemoconcentration is not a major mechanism. Elevated urinary calcium excretion has been documented indicating increased calcium input into the extracellular fluid. Bone biopsies in three patients with hypercalcaemia and Addison’s disease demonstrated depressed osteoblastic and osteoclastic activities at the trabecular surfaces. However, calcium levels are mostly regulated by active transport of calcium out of interstitial bone fluid into the blood by the osteocyte ‘lining cells’.

Cardiac contractile function is diminished by acidosis. Mechanisms include altered intracellular calcium mobilisation and decreased myofibrillar...
calcium sensitivity. However, the pH of the reported patient was 7.3 at presentation and was in the range 7.35-7.45 during the period of deteriorating cardiac function in the intensive care unit.

Mitochondrial disorders can be a cause of both cardiomyopathy and autoimmune adrenal disease. Our patient did not demonstrate associated clinical features, such as ptosis, ophthalmoparesis, peripheral myopathy or pigmentary retinopathy.

This report describes the onset of congestive cardiac failure more than 24 hours after institution of treatment and after initial improvement. Chronic myocardial glucocorticoid deficiency was likely the predominant pathogenetic mechanism causing the deterioration in cardiac function. Hydration therapy partially corrected the hypovolaemic state, with water and sodium retention due to commencement of glucocorticoid and mineralocorticoid therapy. However, recovery of cardiac function was slower. Hence there was likely diminished functional reserve of the myocardium to cope with the increased intravascular volume due to partial correction of hypovolaemia. There may be a role for increased initial glucocorticoid replacement or slower rehydration. Due to the mechanisms stated previously, inotropic agents may be poorly effective until large doses of glucocorticoid have been administered.

This report highlights the importance of evaluating myocardial function in patients with longstanding glucocorticoid deficiency and being alert to the potential complication of cardiomyopathy as treatment is commenced. High doses of glucocorticoids may be required in this context. Cardiomyopathy should also be remembered as a possible presentation of glucocorticoid deficiency.

ACKNOWLEDGEMENTS

Dr. Louise Conwell's Clinical Research Scholarship was supported by the Royal Children's Hospital Foundation, Brisbane.

REFERENCES


JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM